European Commission
Merck's Keytruda Plus Chemo Approved in Europe for Certain Gastroesophageal Cancers
The European Commission approved the combination as first-line treatment for PD-L1-expressing advanced esophageal cancer or HER2-negative GEJ cancer.
BMS' Opdivo, Yervoy Combo Approved for dMMR, MSI-High Colorectal Cancer in Europe
The combination treatment has already been approved in the US and recommended for approval in the UK for this indication.
European Commission Approves Regeneron, Sanofi's Libtayo for First-Line NSCLC
Based on the results of the EMPOWER-Lung 1 trial, the regulators approved the drug in advanced NSCLC patients with high PD-L1 expression.
CHMP Recommends Merck's Keytruda Plus Chemo for Certain Esophageal, Gastroesophageal Cancers
The EMA committee recommended approval for pembrolizumab plus chemo as first-line treatment for patients whose tumors express a PD-L1 CPS of 10 or more.
European Commission Approves GSK's Dostarlimab in Endometrial Cancer
The approval marks the first anti-PD1 antibody available in Europe to treat recurrent or advanced endometrial cancer.